ZHONGZHIPHARM released its annual performance, with a profit attributable to shareholders of 95.212 million yuan, a year-on-year decrease of 41.51%
ZHONGZHIPHARM released its annual results for the year ending December 31, 2024, with revenue of 2.215 billion yuan, a year-on-year increase of 8.05%; profit attributable to shareholders of 95.212 million yuan, a year-on-year decrease of 41.51%; basic earnings per share of 0.11 yuan, and a proposed final dividend of 5 Hong Kong cents per share. Pharmaceutical revenue grew by approximately 14.7%, accounting for 73.3% of total revenue
According to the Zhitong Finance APP, ZHONGZHIPHARM (03737) announced its annual results for the year ending December 31, 2024, with revenue of RMB 2.215 billion, an increase of 8.05% year-on-year; profit attributable to shareholders of RMB 95.212 million, a decrease of 41.51% year-on-year; basic earnings per share of RMB 0.11; and a proposed final dividend of HKD 0.05 per share.
The announcement stated that revenue from pharmaceuticals grew by approximately 14.7%, reaching RMB 1.624 billion for the year ending December 31, 2024 (2023: RMB 1.416 billion), accounting for 73.3% of total revenue for the year (2023: 69.1%). The increase in revenue was mainly due to the group's adaptation to market changes, with a sales strategy that increased market investment in traditional Chinese medicine while focusing on broken wall decoction pieces and proprietary Chinese medicines
